FDA adds boxed warning to a multiple sclerosis drug, citing rare but severe risk. Today, the FDA issued a warning about the risk of anaphylaxis, a rare but life-threatening allergic reaction ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

a rare but severe allergic reaction associated with glatiramer acetate, a medication used to treat relapsing forms of multiple sclerosis (MS). Anaphylaxis can occur at any time during treatment ...

A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...

This report highlights the diagnostic challenges of SM, emphasize its underrecognized role in osteoporosis and fragility fractures, and advocates for ...

Life-changing treatment for hand tremors in Parkinson’s and dystonia patients: Doctor reveals all you need to know about how ...

Imagine living with a condition so debilitating it disrupts daily life, yet being told you don’t qualify for disability benefits. This is ...

The following is a summary of “Chronic graft-versus-host disease myelitis successfully treated with rituximab,” published in ...

Explore a rare case of systemic mastocytosis in a young adult, highlighting its role in unexplained osteoporosis and the need for early testing.

The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability ...

Recent research highlights a concerning trend: pregnant people with multiple sclerosis are more prone to mental illnesses ...

The drug, glatiramer acetate, is approved to treat patients with relapsing forms of multiple sclerosis ... including severe rash or shock, which is a life-threatening condition.